Aurinia Pharmaceuticals Inc. (AUPH) Operating Margin
- Operating margin · 12 months: Value 48.39%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 48.39% | Operating income / revenue. Period ending 2026-06-30. $150.75M ÷ $311.51M × 100 ≈ 48.39% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 150.75M USD | Operating Income (Loss) |
| Revenue | 311.51M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 39.85M USD | Research and Development Expense |
| Selling, general and administration | (m) | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $150.75M | $311.51M | (m) | $39.85M | (m) | 48.39% |
| 2026-03-31 | $124.49M | $298.30M | (m) | $34.23M | (m) | 41.73% |
| 2025-12-31 | $104.91M | $283.06M | (m) | $32.51M | (m) | 37.06% |
| 2025-09-30 | $70.01M | $265.81M | (m) | $29.72M | (m) | 26.34% |
| 2025-06-30 | $52.01M | $260.11M | (m) | $24.33M | (m) | 19.99% |
| 2025-03-31 | $30.41M | $247.29M | (m) | $20.98M | (m) | 12.30% |
| 2024-12-31 | $-4.69M | $235.13M | (m) | $20.79M | (m) | -1.99% |
| 2024-09-30 | $-32.69M | $220.36M | (m) | $22.91M | (m) | -14.84% |
| 2024-06-30 | $-60.70M | $207.10M | (m) | $33.46M | (m) | -29.31% |
| 2024-03-31 | $-75.36M | $191.41M | (m) | $42.03M | (m) | -39.37% |
| 2023-12-31 | $-91.69M | $175.51M | (m) | $49.64M | $195.00M | -52.24% |
| 2023-09-30 | $-90.12M | $158.85M | (m) | $49.28M | (m) | -56.73% |
| 2023-06-30 | $-83.35M | $160.12M | (m) | $46.65M | (m) | -52.06% |
| 2023-03-31 | $-103.17M | $146.81M | (m) | $45.53M | (m) | -70.27% |
| 2022-12-31 | $-111.47M | $134.03M | (m) | $44.99M | $196.40M | -83.17% |
| 2022-09-30 | $-116.08M | $129.00M | (m) | $46.27M | (m) | -89.98% |
| 2022-06-30 | $-156.93M | $87.89M | (m) | $55.36M | (m) | -178.56% |
| 2022-03-31 | $-168.07M | $66.32M | (m) | $53.93M | (m) | -253.44% |
| 2021-12-31 | $-180.74M | $45.60M | (m) | $51.14M | $171.40M | -396.31% |
| 2021-09-30 | $-156.08M | $72.23M | (m) | $53.16M | (m) | -216.09% |
| 2021-06-30 | $-148.04M | $57.59M | (m) | $45.34M | (m) | -257.05% |
| 2021-03-31 | $-127.77M | $51.00M | (m) | $46.33M | (m) | -250.53% |
| 2020-12-31 | $-104.29M | $50.12M | (m) | $50.33M | (m) | -208.09% |
| 2020-09-30 | $-131.08M | $117.00K | (m) | (m) | (m) | -112033.33% |
| 2020-06-30 | $-112.83M | $318.00K | (m) | (m) | (m) | -35481.76% |
| 2020-03-31 | $-103.11M | $318.00K | (m) | (m) | (m) | -32425.16% |
| 2019-12-31 | $-90.94M | $318.00K | (m) | $52.87M | (m) | -28598.43% |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $-55.24M | $463.00K | (m) | $41.38M | (m) | -11930.89% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |